June 2, 2022 - Due to the recent COVID-19-related shutdown of a factory in Shanghai, there is a nationwide shortage of intravenous iodinated contrast media (e.g., iohexol) which is expected to last for several more weeks. As a consequence of… Read More
April 21, 2022 - Imaging Endpoints is regularly looking at different and new designs for clinical trials. Our science expertise, and knowledge of the science behind the imaging, gives us the ability on a multidisciplinary level to develop the best… Read More
April 7, 2022 - The fusion of new therapeutics, imaging, and biomarker development is directing us into an advanced realm of healthcare delivery. Imaging Endpoints understands that every data point counts and is critical for successful trial completion, from Phase… Read More
March 31, 2022 - Imaging Endpoints congratulates Novartis for its recent Food and Drug Administration (FDA) approval of Locametz® and Pluvicto™. The FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) for the treatment of adult patients with prostate-specific membrane antigen… Read More
March 23, 2022 - Last week Imaging Endpoints had a great opportunity to join the entire stakeholder community at the Immuno-Oncology 360° Conference (“IO360”) as a founding sponsor for the 8th consecutive year. Our CMO, Ron Korn, MD, Ph.D. presented… Read More
Featured Webinar:
Radiologic Analysis of COVID-19 Infection
June 23, 2020
